Blog

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in
Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

Conditions:   Type 1 Diabetes Mellitus;   Pregnancy in Diabetics
Intervention:   Device: Dexcom G6 CGM
Sponsors:   Sansum Diabetes Research Institute;   Harvard John A. Paulson School of Engineering and Applied Sciences;   Mayo Clinic;   Icahn School of Medicine at Mount Sinai
Recruiting
ClinicalTrials.gov: Obstetrics | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

Condition:   Indolent Systemic Mastocytosis
Interventions:   Other: Placebo;   Biological: Sarilumab
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in
Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

Conditions:   Type 1 Diabetes Mellitus;   Pregnancy in Diabetics
Intervention:   Device: Dexcom G6 CGM
Sponsors:   Sansum Diabetes Research Institute;   Harvard John A. Paulson School of Engineering and Applied Sciences;   Mayo Clinic;   Icahn School of Medicine at Mount Sinai
Recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions:   Procedure: CS1-CAR T Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Leukapheresis
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in
Early Prostate Cancer: Predicting Treatment Response

Condition:   Prostate Cancer
Intervention:  
Sponsors:   University of California, Irvine;   University of California, Los Angeles;   Cedars-Sinai Medical Center;   VA Medical Center-West Los Angeles;   VA Long Beach Healthcare System
Recruiting
ClinicalTrials.gov: Genetic_Disease | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in